Viewing nowLaraCap 75 mg (Pregabalin)
Pregabalin 75mg
Hard capsule · Prescription medication
Youyoung Pharmaceutical Co., Ltd.

MFDS item code 201109030 · Approved 2011.10.24 · Insurance code 648203510
Treatment of neuropathic pain, treatment of fibromyalgia, adjunctive treatment of partial-onset seizures
This medication is used for the treatment of peripheral and central neuropathic pain in adults. It is also administered as an adjunct for patients with partial seizures in epilepsy to help alleviate their symptoms. Additionally, it is effective for the treatment of fibromyalgia. It is widely used for a variety of neurological disorders and pain management.
This medicine should be administered orally as pregabalin in two divided doses per day, with or without food. Because this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’.) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’.) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg to 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys as unchanged drug. Because clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above equation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin Dosage Based on Renal Function Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Initial dose 25, maximum dose 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the administration schedule. b: Supplemental dose refers to a dose administered once as an additional dose. 6. Patients with Hepatic Impairment Dose adjustment is not required in patients with hepatic impairment. 8. Older Adults (65 years of age or older) Dose reduction may be necessary in older adults with impaired renal function.
Children under 12 years of age: Administration is not recommended. Adolescent patients aged 12 ~17 years: Administration is not recommended.
This medication may increase the risk of suicidal thoughts or behavior, so if mood changes or unusual behavior occur during treatment, consult a healthcare provider immediately. Do not use if you are allergic to any of the components of this medication or have certain genetic disorders. Diabetic patients should be cautious as weight gain may necessitate adjustments to blood glucose control medications. If symptoms of hypersensitivity such as swelling of the face or around the mouth occur, discontinue use immediately. Elderly patients may be at increased risk of falls due to dizziness or drowsiness, so caution is required. Visual disturbances or changes in eyesight may occur, so inform a healthcare professional if these symptoms emerge. Discontinuing this medication suddenly may lead to withdrawal symptoms such as insomnia, headache, and anxiety, so it should be tapered off gradually under a healthcare provider's guidance. Patients with a history of substance abuse may have an increased risk of dependence on this medication; consultation with a healthcare provider before use is necessary. Patients with decreased kidney function may require dosage adjustments. Patients with severe heart disease need to be cautious while taking this medication. Taking this medication with opioid pain relievers may increase the central nervous system depressant effects, so caution is advised. In the early stages of pregnancy, there is a risk of fetal malformation, so women who are pregnant or planning to become pregnant must consult before use. Breastfeeding women should consider that this medication may pass into breast milk and may need to stop breastfeeding or this medication. Avoid driving or operating dangerous machinery until dizziness and drowsiness have resolved completely. In case of overdose, confusion, drowsiness, seizures, etc. may manifest, so immediate emergency treatment is required. Keep out of reach of children and avoid transferring to other containers.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly closed container to protect it from air and moisture. It is advisable to keep the medicine at room temperature between 15 to 30 degrees Celsius, away from very hot or very cold locations.
A hard capsule with a reddish-brown upper part and a white lower part containing a white powder that is white or light yellow in color.
30 capsules/bottle, 60 capsules/bottle, 100 capsules/bottle (for export), 30 capsules/PTP (for export), 100 capsules/PTP (for export)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 75mg
Hard capsule · Prescription medication
Youyoung Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.